Ajanta Pharma Limited , a prominent pharmaceutical company, has reported significant developments in its shareholding structure. Two promoters of the company have released pledges on their shares, as disclosed in recent regulatory filings.

Key Details of the Pledge Releases

Latest Regulatory Filing Details

According to the latest regulatory disclosure, Aayush Agrawal, acting as Trustee of Aayush Agrawal Trust, has formally communicated the pledge release to both BSE Limited and National Stock Exchange of India. The disclosure was made under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Regulatory Compliance

Ajanta Pharma has adhered to the regulatory requirements by making the necessary disclosures to both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). These actions align with the Securities and Exchange Board of India (SEBI) regulations, specifically under the substantial acquisition and takeover regulations.

Implications of Pledge Releases

The release of pledged shares typically indicates a positive development for the company and its shareholders. It suggests that the promoters have been able to fulfill financial obligations or have found alternative means of financing, reducing the overall encumbrance on the company's shares. The specific mention of "upward movement in market price" as a reason for Aayush Agrawal's pledge release indicates favorable market conditions for the stock.

Transparency in Corporate Governance

By promptly disclosing this information, Ajanta Pharma demonstrates its commitment to transparency and good corporate governance practices. Such disclosures help investors and market participants make informed decisions based on the latest changes in the company's shareholding pattern. The regulatory filings include detailed information about the share encumbrance releases, as mandated by SEBI's substantial acquisition and takeover regulations.

Ajanta Pharma , a specialty pharmaceutical formulation company, has announced Monday, November 10, 2025, as the record date for its first interim dividend payment. The company made this disclosure to the BSE and NSE stock exchanges, demonstrating its commitment to shareholder value.

Dividend Details

The Board of Directors of Ajanta Pharma have approved a first interim dividend for the financial year 2026. Key details of the dividend are as follows:

Financial Performance

The dividend announcement comes on the heels of Ajanta Pharma's financial performance for the second quarter and first half of FY 2026:

• Q2 FY 2026 revenue from operations increased by 14% to Rs. 1,354.00 crore
• Q2 FY 2026 profit after tax (PAT) grew by 20% to Rs. 260.00 crore
• H1 FY 2026 revenue from operations rose by 14% to Rs. 2,656.00 crore
• H1 FY 2026 PAT increased by 12% to Rs. 516.00 crore

Segment Performance

Ajanta Pharma's growth was driven by performances across its business segments:

Market Position

According to IQVIA MAT September 2025 data, Ajanta Pharma's India branded generics performance exceeded the Indian Pharmaceutical Market (IPM) growth by 32%. The company showed growth in key therapeutic areas:

Investor Information

Investors and shareholders should take note of the November 10, 2025 record date to be eligible for the interim dividend payment.

This dividend announcement, coupled with the company's financial performance, underscores Ajanta Pharma's commitment to delivering value to its shareholders while maintaining growth across its business segments.